ADRs of Novartis (NVS) were marginally higher pre-market Thursday after the Swiss drugmaker announced a new analysis from Phase III clinical trials that reinforce the long-term efficacy profile of Gilenya for treating patients with relapsing multiple sclerosis.
The analysis evaluated the number of Gilenya patients with relapsing multiple sclerosis who achieved ‘no evidence of disease activity’ (NEDA-4) every year over a seven-year period.
The data showed that in the first year, 27.1% of Gilenya patients achieved NEDA-4 compared to 9.1% on placebo. Switching from placebo to Gilenya after year two more than doubled the proportion of patients achieving NEDA-4 (12.7% to 27.4%) in year three. Of those patients on continuous Gilenya treatment, 31.2% to 44.8% had NEDA-4-status in each of the years three to seven.
NVS was moving in the lower half of the 52-week range of $84.17 to $106.84.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...